-DOCSTART- -X- O
In -X- _ O
the -X- _ O
past -X- _ O
two -X- _ O
decades -X- _ O
there -X- _ O
has -X- _ O
been -X- _ O
a -X- _ O
significant -X- _ O
expansion -X- _ O
in -X- _ O
the -X- _ O
number -X- _ O
of -X- _ O
new -X- _ O
therapeutic -X- _ O
monoclonal -X- _ B-Intervention
antibodies -X- _ I-Intervention
( -X- _ I-Intervention
mAbs -X- _ I-Intervention
) -X- _ I-Intervention
that -X- _ O
are -X- _ O
approved -X- _ O
by -X- _ O
regulators. -X- _ O
The -X- _ O
discovery -X- _ O
of -X- _ O
these -X- _ O
new -X- _ O
medicines -X- _ O
has -X- _ O
been -X- _ O
driven -X- _ O
primarily -X- _ O
by -X- _ O
new -X- _ O
approaches -X- _ O
in -X- _ O
inflammatory -X- _ O
diseases -X- _ O
and -X- _ O
oncology -X- _ O
, -X- _ O
especially -X- _ O
in -X- _ O
immuno-oncology. -X- _ O
Other -X- _ O
recent -X- _ O
successes -X- _ O
have -X- _ O
included -X- _ O
new -X- _ O
antibodies -X- _ O
for -X- _ O
use -X- _ O
in -X- _ O
viral -X- _ O
diseases -X- _ O
, -X- _ O
including -X- _ O
HIV. -X- _ O
The -X- _ O
perception -X- _ O
of -X- _ O
very -X- _ O
high -X- _ O
costs -X- _ O
associated -X- _ O
with -X- _ O
mAbs -X- _ O
has -X- _ O
led -X- _ O
to -X- _ O
the -X- _ O
assumption -X- _ O
that -X- _ O
they -X- _ O
play -X- _ O
no -X- _ O
role -X- _ O
in -X- _ O
prophylaxis -X- _ O
for -X- _ O
diseases -X- _ O
of -X- _ O
poverty. -X- _ O
However -X- _ O
, -X- _ O
improvements -X- _ O
in -X- _ O
antibody-expression -X- _ O
yields -X- _ O
and -X- _ O
manufacturing -X- _ O
processes -X- _ O
indicate -X- _ O
this -X- _ O
is -X- _ O
a -X- _ O
cost-effective -X- _ O
option -X- _ O
for -X- _ O
providing -X- _ O
protection -X- _ O
from -X- _ O
many -X- _ O
types -X- _ O
of -X- _ O
infection -X- _ O
that -X- _ O
should -X- _ O
be -X- _ O
revisited. -X- _ O
Recent -X- _ O
technology -X- _ O
developments -X- _ O
also -X- _ O
indicate -X- _ O
that -X- _ O
several -X- _ O
months -X- _ O
of -X- _ O
protection -X- _ O
could -X- _ O
be -X- _ O
achieved -X- _ O
with -X- _ O
a -X- _ O
single -X- _ O
dose. -X- _ O
Moreover -X- _ O
, -X- _ O
new -X- _ O
methods -X- _ O
in -X- _ O
B -X- _ O
cell -X- _ O
sorting -X- _ O
now -X- _ O
enable -X- _ O
the -X- _ O
systematic -X- _ O
identification -X- _ O
of -X- _ O
high-quality -X- _ O
antibodies -X- _ O
from -X- _ O
humanized -X- _ B-Patient
mice -X- _ I-Patient
, -X- _ O
or -X- _ O
patients. -X- _ B-Patient
This -X- _ O
Review -X- _ O
discusses -X- _ O
the -X- _ O
potential -X- _ B-Outcome
for -X- _ I-Outcome
passive -X- _ I-Outcome
immunization -X- _ I-Outcome
against -X- _ I-Outcome
schistosomiasis -X- _ I-Outcome
, -X- _ O
fungal -X- _ B-Outcome
infections -X- _ I-Outcome
, -X- _ O
dengue -X- _ B-Outcome
, -X- _ O
and -X- _ O
other -X- _ B-Outcome
neglected -X- _ I-Outcome
diseases -X- _ I-Outcome
. -X- _ O

